1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin has been researched along with angiotensin ii in 3 studies
| Studies (1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin) | Trials (1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin) | Recent Studies (post-2010) (1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin) | Studies (angiotensin ii) | Trials (angiotensin ii) | Recent Studies (post-2010) (angiotensin ii) |
|---|---|---|---|---|---|
| 35 | 0 | 0 | 38,152 | 1,089 | 7,413 |
| Protein | Taxonomy | 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin (IC50) | angiotensin ii (IC50) |
|---|---|---|---|
| Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.002 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.002 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0018 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0055 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.004 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.0011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brand, PH; Britton, SL; Metting, PJ | 1 |
| Matsuda, T; Mori, M; Tsushima, H | 1 |
| Reis, DJ; Sun, MK | 1 |
3 other study(ies) available for 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin and angiotensin ii
| Article | Year |
|---|---|
Support of arterial blood pressure by major pressor systems in conscious dogs.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Blood Pressure; Captopril; Dehydration; Dogs; Female; Ganglia, Autonomic; Heart Rate; Hexamethonium; Hexamethonium Compounds; Male; Reference Values; Renin; Vasopressins | 1988 |
Microinjections of angiotensin II into the supraoptic and paraventricular nuclei produce potent antidiureses by vasopressin release mediated through adrenergic and angiotensin receptors.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine Vasopressin; Diuresis; Dose-Response Relationship, Drug; Injections, Intra-Arterial; Injections, Intraventricular; Male; Microinjections; Paraventricular Hypothalamic Nucleus; Phenoxybenzamine; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Angiotensin; Supraoptic Nucleus; Timolol; Vasoconstriction; Vasopressins | 1994 |
Intracisternally applied angiotensin II does not excite reticulospinal vasomotor neurons in anesthetized rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Pressure; Cisterna Magna; Dose-Response Relationship, Drug; Ganglionic Blockers; Hexamethonium; Hypoxia; Iontophoresis; Male; Medulla Oblongata; Rats; Receptors, Angiotensin; Receptors, Vasopressin; Stimulation, Chemical; Vasoconstrictor Agents; Vasomotor System | 1996 |